This according to what emerged from Milan, on the occasion of the presentation of the volume “hepatocellular carcinoma” (edition, Elsevier), which brought together some of the più illustrious oncologists and hepatologists Italian.
“by Applying staging criteria that have prognostic value, we can refer the patient to the best treatment,” says Colombo, director of the division of Gastroenterology 1, Irccs Foundation Maggiore Policlinico Hospital, Mangiagalli and Regina Elena of Milan.
“There is, moreover, a substantial number of cases in which the evolution of the tumour requires treatment choices up-to-date from time to time: it begins with a treatment ablative loco-regional or of restraint, to proceed to surgical approaches, and finally, if the answer is satisfactory, the medical treatment”.
Just on the medical treatment, biological therapies today give more hope to those who previously had no ability to care.
“The data obtained with sorafenib, have opened a new branch of research and clinical interest in the treatment of hepatocellular carcinoma in advanced stage,” says Armando Santoro, director of the department of Oncology and Hematology of Istituto clinico Humanitas of Rozzano (Mi).
“The drug is, in fact, has been shown to significantly improve the survival of patients who until a few years ago were exclusively treated with palliative therapies” (N. M.).
Hepatitis A, B, and C. Symptoms, diagnosis, and treatment
Page published on 12 October 2009